The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity

Terrence J. Pattinson, Charles R. Gibson, Francis K. Manuel, Sheryl L. Bishop, Wayne F. March

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Intraocular pressure (IOP) has been found to increase during microgravity. After peaking in the first few hours of orbital flight, IOP slowly decreases to a level that is slightly elevated above baseline IOP's. These modest elevations in IOP do not require treatment. Just as in 1-G, a clinically significant elevation of IOP that occurred during spaceflight would require treatment. We are not aware of previous studies of the efficacy of IOP lowering agents under conditions of microgravity. Methods: This double-masked, placebo-controlled study measured the IOP's of 11 adult subjects (22 eyes) at baseline, preflight, and zero-gravity aboard the NASA KC-135 aircraft, and postflight. One eye of each of the subjects was treated with betaxolol hydrochloride ophthalmic solution 0.5%, while the contralateral eye was treated with normal saline placebo, for 7 d prior to parabolic flight, IOP's were measured by the Tono-Pen 2, a gravity independent tonometer. Results: A modest, but statistically significant reduction of 2.4 mmHg in mean IOP was noted in betaxolol treated eyes at the time of preflight measurement. During zero-G, the mean IOP's of both betaxolol treated eyes and placebo treated eyes increased approximately 20% over preflight levels. Postflight IOP's were similar to preflight IOP's. Conclusions: The effect of betaxolol on the IOP of eyes treated with for 1 wk prior to exposure to microgravity was statistically significant, but may lack clinical significance in normal eyes. Further research needs to be done to determine the efficacy during microgravity of betaxolol and other agents, in subjects who have upper normal to slightly elevated IOP's at 1 G.

Original languageEnglish (US)
Pages (from-to)1012-1017
Number of pages6
JournalAviation Space and Environmental Medicine
Volume70
Issue number10
StatePublished - Oct 1999

Fingerprint

Betaxolol
Weightlessness
Ophthalmic Solutions
Microgravity
Intraocular Pressure
Placebos
Gravitation
United States National Aeronautics and Space Administration
Space Flight
Aircraft
NASA
Double-Blind Method

Keywords

  • Betaxolol
  • Glaucoma
  • Weightlessness
  • Weightlessness simulation

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Pollution
  • Medicine(all)

Cite this

Pattinson, T. J., Gibson, C. R., Manuel, F. K., Bishop, S. L., & March, W. F. (1999). The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity. Aviation Space and Environmental Medicine, 70(10), 1012-1017.

The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity. / Pattinson, Terrence J.; Gibson, Charles R.; Manuel, Francis K.; Bishop, Sheryl L.; March, Wayne F.

In: Aviation Space and Environmental Medicine, Vol. 70, No. 10, 10.1999, p. 1012-1017.

Research output: Contribution to journalArticle

Pattinson, TJ, Gibson, CR, Manuel, FK, Bishop, SL & March, WF 1999, 'The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity', Aviation Space and Environmental Medicine, vol. 70, no. 10, pp. 1012-1017.
Pattinson, Terrence J. ; Gibson, Charles R. ; Manuel, Francis K. ; Bishop, Sheryl L. ; March, Wayne F. / The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity. In: Aviation Space and Environmental Medicine. 1999 ; Vol. 70, No. 10. pp. 1012-1017.
@article{7f1e132e402c4f47a80a55963360257b,
title = "The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity",
abstract = "Background: Intraocular pressure (IOP) has been found to increase during microgravity. After peaking in the first few hours of orbital flight, IOP slowly decreases to a level that is slightly elevated above baseline IOP's. These modest elevations in IOP do not require treatment. Just as in 1-G, a clinically significant elevation of IOP that occurred during spaceflight would require treatment. We are not aware of previous studies of the efficacy of IOP lowering agents under conditions of microgravity. Methods: This double-masked, placebo-controlled study measured the IOP's of 11 adult subjects (22 eyes) at baseline, preflight, and zero-gravity aboard the NASA KC-135 aircraft, and postflight. One eye of each of the subjects was treated with betaxolol hydrochloride ophthalmic solution 0.5{\%}, while the contralateral eye was treated with normal saline placebo, for 7 d prior to parabolic flight, IOP's were measured by the Tono-Pen 2, a gravity independent tonometer. Results: A modest, but statistically significant reduction of 2.4 mmHg in mean IOP was noted in betaxolol treated eyes at the time of preflight measurement. During zero-G, the mean IOP's of both betaxolol treated eyes and placebo treated eyes increased approximately 20{\%} over preflight levels. Postflight IOP's were similar to preflight IOP's. Conclusions: The effect of betaxolol on the IOP of eyes treated with for 1 wk prior to exposure to microgravity was statistically significant, but may lack clinical significance in normal eyes. Further research needs to be done to determine the efficacy during microgravity of betaxolol and other agents, in subjects who have upper normal to slightly elevated IOP's at 1 G.",
keywords = "Betaxolol, Glaucoma, Weightlessness, Weightlessness simulation",
author = "Pattinson, {Terrence J.} and Gibson, {Charles R.} and Manuel, {Francis K.} and Bishop, {Sheryl L.} and March, {Wayne F.}",
year = "1999",
month = "10",
language = "English (US)",
volume = "70",
pages = "1012--1017",
journal = "Aerospace medicine and human performance",
issn = "2375-6314",
publisher = "Aerospace Medical Association",
number = "10",

}

TY - JOUR

T1 - The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity

AU - Pattinson, Terrence J.

AU - Gibson, Charles R.

AU - Manuel, Francis K.

AU - Bishop, Sheryl L.

AU - March, Wayne F.

PY - 1999/10

Y1 - 1999/10

N2 - Background: Intraocular pressure (IOP) has been found to increase during microgravity. After peaking in the first few hours of orbital flight, IOP slowly decreases to a level that is slightly elevated above baseline IOP's. These modest elevations in IOP do not require treatment. Just as in 1-G, a clinically significant elevation of IOP that occurred during spaceflight would require treatment. We are not aware of previous studies of the efficacy of IOP lowering agents under conditions of microgravity. Methods: This double-masked, placebo-controlled study measured the IOP's of 11 adult subjects (22 eyes) at baseline, preflight, and zero-gravity aboard the NASA KC-135 aircraft, and postflight. One eye of each of the subjects was treated with betaxolol hydrochloride ophthalmic solution 0.5%, while the contralateral eye was treated with normal saline placebo, for 7 d prior to parabolic flight, IOP's were measured by the Tono-Pen 2, a gravity independent tonometer. Results: A modest, but statistically significant reduction of 2.4 mmHg in mean IOP was noted in betaxolol treated eyes at the time of preflight measurement. During zero-G, the mean IOP's of both betaxolol treated eyes and placebo treated eyes increased approximately 20% over preflight levels. Postflight IOP's were similar to preflight IOP's. Conclusions: The effect of betaxolol on the IOP of eyes treated with for 1 wk prior to exposure to microgravity was statistically significant, but may lack clinical significance in normal eyes. Further research needs to be done to determine the efficacy during microgravity of betaxolol and other agents, in subjects who have upper normal to slightly elevated IOP's at 1 G.

AB - Background: Intraocular pressure (IOP) has been found to increase during microgravity. After peaking in the first few hours of orbital flight, IOP slowly decreases to a level that is slightly elevated above baseline IOP's. These modest elevations in IOP do not require treatment. Just as in 1-G, a clinically significant elevation of IOP that occurred during spaceflight would require treatment. We are not aware of previous studies of the efficacy of IOP lowering agents under conditions of microgravity. Methods: This double-masked, placebo-controlled study measured the IOP's of 11 adult subjects (22 eyes) at baseline, preflight, and zero-gravity aboard the NASA KC-135 aircraft, and postflight. One eye of each of the subjects was treated with betaxolol hydrochloride ophthalmic solution 0.5%, while the contralateral eye was treated with normal saline placebo, for 7 d prior to parabolic flight, IOP's were measured by the Tono-Pen 2, a gravity independent tonometer. Results: A modest, but statistically significant reduction of 2.4 mmHg in mean IOP was noted in betaxolol treated eyes at the time of preflight measurement. During zero-G, the mean IOP's of both betaxolol treated eyes and placebo treated eyes increased approximately 20% over preflight levels. Postflight IOP's were similar to preflight IOP's. Conclusions: The effect of betaxolol on the IOP of eyes treated with for 1 wk prior to exposure to microgravity was statistically significant, but may lack clinical significance in normal eyes. Further research needs to be done to determine the efficacy during microgravity of betaxolol and other agents, in subjects who have upper normal to slightly elevated IOP's at 1 G.

KW - Betaxolol

KW - Glaucoma

KW - Weightlessness

KW - Weightlessness simulation

UR - http://www.scopus.com/inward/record.url?scp=0033373841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033373841&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 1012

EP - 1017

JO - Aerospace medicine and human performance

JF - Aerospace medicine and human performance

SN - 2375-6314

IS - 10

ER -